miR‑132 is upregulated in polycystic ovarian syndrome and inhibits granulosa cells viability by targeting Foxa1

Cui,Xiangrong; Jing,Xuan; Liu,Junfen; Bi,Xingyu; Wu,Xueqing

doi:10.3892/mmr.2020.11590

miR‑132 is upregulated in polycystic ovarian syndrome and inhibits granulosa cells viability by targeting Foxa1

Authors:
- Xiangrong Cui
- Xuan Jing
- Junfen Liu
- Xingyu Bi
- Xueqing Wu
View Affiliations

Affiliations: Reproductive Medicine Center, Shanxi Women and Infants Hospital, Affiliate of Shanxi Medical University, Taiyuan, Shanxi 030001, P.R. China, Department of Clinical Laboratory, Shanxi Provincial People's Hospital, Affiliate of Shanxi Medical University, Taiyuan, Shanxi 030001, P.R. China
Published online on: October 14, 2020 https://doi.org/10.3892/mmr.2020.11590
Pages: 5155-5162
Copyright: © Cui et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Polycystic ovary syndrome (PCOS) is one of the most common endocrine metabolic disorders characterized by hyperandrogenism, polycystic ovaries and ovulatory dysfunction. Several studies have suggested that the aberrant expression of microRNAs (miRNAs/miRs) plays an important role in the pathogenesis of PCOS; however, the role and underlying mechanisms of miR‑132 in the development of PCOS remain unclear. In the present study, the expression of miR‑132 in granulosa cells (GCs) derived from 26 patients with PCOS and 30 healthy controls was detected by reverse transcription‑quantitative PCR (RT‑qPCR). The apoptosis of GCs was examined using a TUNEL assay. The human ovarian granulosa‑like tumor cell line, KGN, was cultured for Cell Counting Kit‑8 assays following the overexpression or knockdown of miR‑132. TargetScan was applied to identify the potential targets of miR‑132, which was further verified by a luciferase assay, RT‑qPCR and western blotting. The expression of miR‑132 was decreased in GCs from patients with PCOS. Moreover, the GCs of patients with PCOS exhibited significantly increased apoptotic nuclei. Furthermore, the overexpression of miR‑132 inhibited the viability of KGN cells. In addition, the results verified that miR‑132 directly targeted forkhead box protein A1 (Foxa1), the knockdown of which suppressed KGN cell viability. On the whole, the findings of the present study demonstrated that miR‑132 inhibited cell viability and induced apoptosis by directly interacting with Foxa1. Thus, miR‑132 may be a potential target for the treatment of patients with PCOS.

View Figures

View References

1	Lin J, Huang J, Wang N, Kuang Y and Cai R: Effects of pre-pregnancy body mass index on pregnancy and perinatal outcomes in women with PCOS undergoing frozen embryo transfer. BMC Pregnancy Childbirth. 19:4872019. View Article : Google Scholar : PubMed/NCBI
2	Li S, Qi J, Tao Y, Zhu Q, Huang R, Liao Y, Yue J, Liu W, Zhao H, Yin H and Sun Y: Elevated levels of arachidonic acid metabolites in follicular fluid of PCOS patients. Reproduction. Nov 1–2019.(Epub ahead of print). doi: 10.1530/REP-19-0136.
3	Sagvekar P, Mangoli V, Desai S, Patil A and Mukherjee S: LINE1 CpG-DNA hypomethylation in granulosa cells and blood leukocytes is associated with PCOS and related traits. J Clin Endocrinol Metab. 102:1396–1405. 2017. View Article : Google Scholar : PubMed/NCBI
4	Makrinou E, Drong AW, Christopoulos G, Lerner A, Chapa-Chorda I, Karaderi T, Lavery S, Hardy K, Lindgren CM and Franks S: Genome-wide methylation profiling in granulosa lutein cells of women with polycystic ovary syndrome (PCOS). Mol Cell Endocrinol. 500:1106112019. View Article : Google Scholar : PubMed/NCBI
5	Qiu X, Wei Y, Liu C, Ding C and Zhao S: Hyperandrogen enhances apoptosis of human ovarian granulosa cells via up-regulation and demethylation of PDCD4. Gynecol Endocrinol. 36:333–337. 2019. View Article : Google Scholar : PubMed/NCBI
6	Li Y, Liu YD, Zhou XY, Chen SL, Chen X, Zhe J, Zhang J, Zhang QY and Chen YX: MiR-29a regulates the proliferation, aromatase expression, and estradiol biosynthesis of human granulosa cells in polycystic ovary syndrome. Mol Cell Endocrinol. 498:1105402019. View Article : Google Scholar : PubMed/NCBI
7	Song Y, Yu G, Xiang Y, Li Y, Wan L and Tan L: Altered miR-186 and miR-135a contribute to granulosa cell dysfunction by targeting ESR2: A possible role in polycystic ovary syndrome. Mol Cell Endocrinol. 494:1104782019. View Article : Google Scholar : PubMed/NCBI
8	Chen B, Xu P, Wang J and Zhang C: The role of MiRNA in polycystic ovary syndrome (PCOS). Gene. 706:91–96. 2019. View Article : Google Scholar : PubMed/NCBI
9	Wang W, Li X, Ren L, Yuan C, Han Y and Wang Z: MiR-132 relieves vascular endothelial inflammation and improve endothelial function in atherosclerosis rats by regulating SIRT1. Minerva Endocrinol. 45:158–161. 2019.PubMed/NCBI
10	Han Y, Wang F, Shao L, Huang P and Xu Y: LncRNA TUG1 mediates lipopolysaccharide-induced proliferative inhibition and apoptosis of human periodontal ligament cells by sponging miR-132. Acta Biochim Biophys Sin (Shanghai). 51:1208–1215. 2019.PubMed/NCBI
11	Zhou X, Xiang C and Zheng X: miR-132 serves as a diagnostic biomarker in gestational diabetes mellitus and its regulatory effect on trophoblast cell viability. Diagn Pathol. 14:1192019. View Article : Google Scholar : PubMed/NCBI
12	Wei XC and Lv ZH: MicroRNA-132 inhibits migration, invasion and epithelial-mesenchymal transition via TGFβ1/Smad2 signaling pathway in human bladder cancer. Onco Targets Ther. 12:5937–5945. 2019. View Article : Google Scholar : PubMed/NCBI
13	Zhang XL, Sun BL, Tian SX, Li L, Zhao YC and Shi PP: MicroRNA-132 reverses cisplatin resistance and metastasis in ovarian cancer by the targeted regulation on Bmi-1. Eur Rev Med Pharmacol Sci. 23:3635–3644. 2019.PubMed/NCBI
14	Wu S, Sun H, Zhang Q, Jiang Y, Fang T, Cui I, Yan G and Hu Y: MicroRNA-132 promotes estradiol synthesis in ovarian granulosa cells via translational repression of Nurr1. Reprod Biol Endocrinol. 13:942015. View Article : Google Scholar : PubMed/NCBI
15	Azziz R: Controversy in clinical endocrinology: Diagnosis of polycystic ovarian syndrome: The Rotterdam criteria are premature. J Clin Endocrinol Metab. 91:781–785. 2006. View Article : Google Scholar : PubMed/NCBI
16	Kaur S, Archer KJ, Devi MG, Kriplani A, Strauss JF III and Singh R: Differential gene expression in granulosa cells from polycystic ovary syndrome patients with and without insulin resistance: Identification of susceptibility gene sets through network analysis. J Clin Endocrinol Metab. 97:E2016–E2021. 2012. View Article : Google Scholar : PubMed/NCBI
17	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
18	Li Y, Zhang J, He J, Zhou W, Xiang G and Xu R: MicroRNA-132 cause apoptosis of glioma cells through blockade of the SREBP-1c metabolic pathway related to SIRT1. Biomed Pharmacother. 78:177–184. 2016. View Article : Google Scholar : PubMed/NCBI
19	Mokutani Y, Uemura M, Munakata K, Okuzaki D, Haraguchi N, Takahashi H, Nishimura J, Hata T, Murata K, Takemasa I, et al: down-regulation of microrna-132 is associated with poor prognosis of colorectal cancer. Ann Surg Oncol. 23 (Suppl 5):599–608. 2016. View Article : Google Scholar : PubMed/NCBI
20	Qin J, Ke J, Xu J, Wang F, Zhou Y, Jiang Y and Wang Z: Downregulation of microRNA-132 by DNA hypermethylation is associated with cell invasion in colorectal cancer. Onco Targets Ther. 8:3639–3648. 2015.PubMed/NCBI
21	Liu Y, Li Y, Liu J, Wu Y and Zhu Q: MicroRNA-132 inhibits cell growth and metastasis in osteosarcoma cell lines possibly by targeting Sox4. Int J Oncol. 47:1672–1684. 2015. View Article : Google Scholar : PubMed/NCBI
22	Lei CJ, Li L, Gao X, Zhang J, Pan QY, Long HC, Chen CZ, Ren DF and Zheng G: Hsa-miR-132 inhibits proliferation of hepatic carcinoma cells by targeting YAP. Cell Biochem Funct. 33:326–333. 2015. View Article : Google Scholar : PubMed/NCBI
23	Zhang ZG, Chen WX, Wu YH, Liang HF and Zhang BX: MiR-132 prohibits proliferation, invasion, migration, and metastasis in breast cancer by targeting HN1. Biochem Biophys Res Commun. 454:109–114. 2014. View Article : Google Scholar : PubMed/NCBI
24	Renjie W and Haiqian L: MiR-132, miR-15a and miR-16 synergistically inhibit pituitary tumor cell proliferation, invasion and migration by targeting Sox5. Cancer Lett. 356:568–578. 2015. View Article : Google Scholar : PubMed/NCBI
25	Li Y, Zu L, Wang Y, Wang M, Chen P and Zhou Q: miR-132 inhibits lung cancer cell migration and invasion by targeting SOX4. J Thorac Dis. 7:1563–1569. 2015.PubMed/NCBI
26	Fiedler SD, Carletti MZ, Hong X and Christenson LK: Hormonal regulation of MicroRNA expression in periovulatory mouse mural granulosa cells. Biol Reprod. 79:1030–1037. 2008. View Article : Google Scholar : PubMed/NCBI
27	Fu X, Pereira R, De Angelis C, Veeraraghavan J, Nanda S, Qin L, Cataldo ML, Sethunath V, Mehravaran S, Gutierrez C, et al: FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer. Proc Natl Acad Sci USA. 116:26823–26834. 2019. View Article : Google Scholar
28	Jing X, Liang H, Hao C, Hongxia L and Cui X: Analyses of an epigenetic switch involved in the activation of pioneer factor FOXA1 leading to the prognostic value of estrogen receptor and FOXA1 co-expression in breast cancer. Aging. 11:7442–7456. 2019. View Article : Google Scholar : PubMed/NCBI
29	Gou L, Zou H and Li B: Long noncoding RNA MALAT1 knockdown inhibits progression of anaplastic thyroid carcinoma by regulating miR-200a-3p/FOXA1. Cancer Biol Ther. 20:1355–1365. 2019. View Article : Google Scholar : PubMed/NCBI
30	Stone L: Different FOXA1 classes drive prostate cancer. Nat Rev Urol. 16:5082019. View Article : Google Scholar
31	BenAyed-Guerfali D, Dabbeche-Bouricha E, Ayadi W, Trifa F, Charfi S, Khabir A, Sellami-Boudawara T and Mokdad-Gargouri R: Association of FOXA1 and EMT markers (Twist1 and E-cadherin) in breast cancer. Mol Biol Rep. 46:3247–3255. 2019. View Article : Google Scholar : PubMed/NCBI
32	Wang D, Ren J, Ren H, Fu JL and Yu D: MicroRNA-132 suppresses cell proliferation in human breast cancer by directly targeting FOXA1. Acta Pharmacol Sin. 39:124–131. 2018. View Article : Google Scholar : PubMed/NCBI
33	Chen X, Li M, Zhou H and Zhang L: miR-132 targets FOXA1 and exerts tumor-suppressing functions in thyroid cancer. Oncol Res. 27:431–437. 2019. View Article : Google Scholar : PubMed/NCBI
34	Li YL, Zhao YG, Chen B and Li XF: MicroRNA-132 sensitizes nasopharyngeal carcinoma cells to cisplatin through regulation of forkhead box A1 protein. Pharmazie. 71:715–718. 2016.PubMed/NCBI
35	Sang Q, Yao Z, Wang H, Feng R, Wang H, Zhao X, Xing Q, Jin L, He L, Wu L and Wang L: Identification of microRNAs in human follicular fluid: characterization of microRNAs that govern steroidogenesis in vitro and are associated with polycystic ovary syndrome in vivo. J Clin Endocrinol Metab. 98:3068–3079. 2013. View Article : Google Scholar : PubMed/NCBI
36	Kranc W, Budna J, Kahan R, Chachuła A, Bryja A, Ciesiółka S, Borys S, Antosik MP, Bukowska D, Brussow KP, et al: Molecular basis of growth, proliferation, and differentiation of mammalian follicular granulosa cells. J Biol Regul Homeost Agents. 31:1–8. 2017.PubMed/NCBI
37	Thomas FH and Vanderhyden BC: Oocyte-granulosa cell interactions during mouse follicular development: Regulation of kit ligand expression and its role in oocyte growth. Reprod Biol Endocrinol. 4:192006. View Article : Google Scholar : PubMed/NCBI